Omeros Participates in Investor Conference Focused on COVID-19 Therapeutics in Development
29 October 2020 - 12:00AM
Business Wire
Omeros Corporation (Nasdaq: OMER) announced that results from
its compassionate use study evaluating narsoplimab in COVID-19
patients in Italy will be shared during a virtual event being
hosted today for registered participants only by ROTH Capital
Partners entitled COVID-19 Therapeutics in Development: Beyond
Gilead, Regeneron and Lilly. The presentation, which is part of a
session on immune modulators to ameliorate COVID-19, is being made
by Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive
officer. Dr. Demopulos’ slide presentation from the conference
session can be viewed at
https://investor.omeros.com/presentations.
Omeros previously announced positive results from the treatment
with narsoplimab of six critically ill COVID-19 patients under a
compassionate use protocol in Bergamo, Italy. All patients
initially required mechanical ventilation and, following treatment
with narsoplimab, all recovered, survived and were discharged from
the hospital. Five to six months following discharge, none of the
patients showed any clinical or laboratory evidence of longer-term
effects from COVID-19. Additional compassionate use with
narsoplimab is ongoing in Bergamo.
About Narsoplimab Narsoplimab, also known as “OMS721,” is
an investigational human monoclonal antibody targeting
mannan-binding lectin-associated serine protease-2 (MASP-2), a
novel pro-inflammatory protein target and the effector enzyme of
the lectin pathway of complement. Importantly, inhibition of MASP-2
does not appear to interfere with the antibody-dependent classical
complement activation pathway, which is a critical component of the
acquired immune response to infection. Omeros controls the
worldwide rights to MASP-2 and all therapeutics targeting
MASP-2.
Phase 3 clinical programs are in progress for narsoplimab in
hematopoietic stem cell transplant-associated thrombotic
microangiopathy (HSCT-TMA), in immunoglobulin A (IgA) nephropathy,
and in atypical hemolytic uremic syndrome (aHUS). The FDA has
granted narsoplimab breakthrough therapy designations for HSCT-TMA
and for IgA nephropathy; orphan drug status for the prevention
(inhibition) of complement-mediated thrombotic microangiopathies,
for the treatment of HSCT-TMA and for the treatment of IgA
nephropathy; and fast track designation for the treatment of
patients with aHUS. The European Medicines Agency has granted
orphan drug designation to narsoplimab for treatment in HSCT and
for treatment of primary IgA nephropathy.
About Omeros Corporation Omeros is a commercial-stage
biopharmaceutical company committed to discovering, developing and
commercializing small-molecule and protein therapeutics for
large-market and orphan indications targeting inflammation,
complement-mediated diseases, disorders of the central nervous
system and immune-related diseases, including cancers. In addition
to its commercial product OMIDRIA (phenylephrine and ketorolac
intraocular solution) 1%/0.3%, Omeros has multiple late-stage
clinical development programs focused on complement-mediated
disorders, including COVID-19, and substance abuse. A rolling
biologics license application for narsoplimab, the company’s lead
MASP-2 inhibitor, in hematopoietic stem cell transplant-associated
thrombotic microangiopathy is being completed for submission to the
U.S. FDA. Omeros also has a diverse group of preclinical programs
including GPR174, a novel target in immuno-oncology that modulates
a new cancer immunity axis recently discovered by Omeros.
Small-molecule inhibitors of GPR174 are part of Omeros’ proprietary
G protein-coupled receptor (GPCR) platform through which it
controls 54 new GPCR drug targets and their corresponding
compounds. The company also exclusively possesses a novel
antibody-generating platform.
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, which are subject to the “safe harbor” created by
those sections for such statements. All statements other than
statements of historical fact are forward-looking statements, which
are often indicated by terms such as “anticipate,” “believe,”
“can,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely”,
“look forward to,” “may,” “on track,” “plan,” “potential,”
“predict,” “project,” “prospects,” “scheduled,” “should,” “slated,”
“targeting,” “will,” “would” and similar expressions and variations
thereof. Forward-looking statements, including statements regarding
anticipated regulatory submissions, the timing and results of
ongoing or anticipated clinical trials, and the therapeutic
application of Omeros’ investigational product, are based on
management’s beliefs and assumptions and on information available
to management only as of the date of this press release. Omeros’
actual results could differ materially from those anticipated in
these forward-looking statements for many reasons, including,
without limitation, availability and timing of data from clinical
trials and the results of such trials, unproven preclinical and
clinical development activities, regulatory oversight, intellectual
property claims, competitive developments, litigation, and the
risks, uncertainties and other factors described under the heading
“Risk Factors” in the company’s Annual Report on Form 10-K for the
year ended December 31, 2019, filed with the Securities and
Exchange Commission (SEC) on March 2, 2020, as supplemented by its
Quarterly Report on Form 10-Q filed with the SEC on August 10, 2020
and subsequent filings with the SEC. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and the company
assumes no obligation to update these forward-looking statements,
whether as a result of any new information, future events or
otherwise, except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201028005499/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations 360.668.3701 jennifer@cwcomm.org
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2024 to May 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From May 2023 to May 2024